Congress Won’t Act on Insulin Prices for Commercial Market

Although Congress is on the brink of passing a landmark prescription drug price reform bill as part of the Inflation Reduction Act (IRA) — Democratic leadership in the House of Representatives plans to vote on the bill Friday — the legislation will not include any provisions that impose price controls on insulin sold to patients with commercial insurance. D.C. insiders tell AIS Health, a division of MMIT, that they do not expect separate, standalone legislation to make it through Congress any time soon, which shines a spotlight on new insulin benefits announced by major carriers like UnitedHealth Group.

© 2025 MMIT
AIS Health Staff

AIS Health Staff

Related Posts

optum-logo
July 28

UnitedHealth Eyes No Out-of-Pocket Costs for Certain Drugs; Other Large Payers May Follow Suit

READ MORE
washington-dc-united-states-capitol-on-capitol-hill
July 29

At the Eleventh Hour, Democrats May Extend ACA Subsidies, Tackle Drug Pricing

READ MORE
capitol-hill
August 5

Telehealth, Insulin Reforms Unlikely to Pass Senate Before Winter

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today